Ask a research question about Chronic_Obstructive_Pulmonary_Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Chronic_Obstructive_Pulmonary_Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-22T20:53:03Z'
category: Complex
parents:
- Respiratory Disease
- Smoking-Related Disease
has_subtypes:
- name: Chronic Bronchitis
description: Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
evidence:
- reference: PMID:23204254
reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
explanation: The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
- reference: PMID:27264777
reference_title: "Management of chronic obstructive pulmonary disease beyond the lungs."
supports: SUPPORT
snippet: Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics.
explanation: The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.
- reference: PMID:22753831
reference_title: "Chronic cough and sputum production: a clinical COPD phenotype?"
supports: SUPPORT
snippet: 'Chronic cough and sputum production: a clinical COPD phenotype?'
explanation: The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.
- name: Emphysema
description: Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.
evidence:
- reference: PMID:33926668
reference_title: "Alpha(1)-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery."
supports: SUPPORT
snippet: 'Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema.'
explanation: This reference reiterates the point that emphysema is a recognized subtype of COPD.
- reference: PMID:21178627
reference_title: "Emphysema and chronic obstructive pulmonary disease in coal miners."
supports: SUPPORT
snippet: Latest studies further support the association of emphysema and COPD with coal dust exposure.
explanation: This confirms that emphysema is considered a subtype of COPD, further supporting the statement.
prevalence:
- population: Global
percentage: 11.7
evidence:
- reference: PMID:35261410
reference_title: "Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis."
supports: NO_EVIDENCE
snippet: 'The estimated pooled prevalence of COPD was 11.1% (95% confidence interval, CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal criteria.'
explanation: The study provides prevalence data for specific regions (e.g., South Asia) but does not mention a global prevalence rate of 11.7%.
- reference: PMID:37461046
reference_title: "Global incidence, prevalence and disease burden of silicosis: 30 years' overview and forecasted trends."
supports: NO_EVIDENCE
snippet: Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored.
explanation: This study focuses on the global incidence, prevalence, and disease burden of silicosis, not COPD.
progression:
- phase: Onset
notes: Typically begins in individuals over the age of 40.
evidence:
- reference: PMID:26154786
reference_title: "Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease."
supports: PARTIAL
snippet: Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation.
explanation: The literature suggests that COPD can develop in individuals with low FEV1 before the age of 40. While this supports the idea that COPD typically begins in individuals over 40, it also indicates that it can start earlier in some cases.
- reference: PMID:19934351
reference_title: "The aging lung and chronic obstructive pulmonary disease: similarity and difference."
supports: SUPPORT
snippet: There is growing evidence of higher prevalence of chronic obstructive pulmonary disease (COPD) in the elderly. Age-associated changes in the structure and function of the lung may increase a pathogenetic susceptibility to COPD.
explanation: This reference supports the statement that COPD typically begins in individuals over the age of 40, particularly due to age-associated changes in lung structure and function.
pathophysiology:
- name: Airflow Limitation
description: Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.
cell_types:
- preferred_term: Epithelial Cell
term:
id: CL:0000066
label: epithelial cell
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
- preferred_term: airway remodeling
description: Structural changes in airway architecture
locations:
- preferred_term: bronchus
term:
id: UBERON:0002185
label: bronchus
- preferred_term: small airway
description: Terminal and respiratory bronchioles
downstream:
- target: Progressive Respiratory Impairment
description: Chronic airway inflammation and remodeling lead to progressive airflow obstruction and respiratory decline.
evidence:
- reference: PMID:39046133
reference_title: "Small airways disease in chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Chronic exposure to smoking and noxious particles or gases induces inflammation and remodeling, leading to airway obstruction and SAD, eventually resulting in complete airway loss.
explanation: This 2024 review establishes that chronic inflammation and remodeling cause irreversible airflow limitation and progressive respiratory decline in COPD.
evidence:
- reference: PMID:23204254
reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse
explanation: This study describes how mucus build-up and epithelial remodeling lead to airflow obstruction in COPD.
- reference: PMID:36108172
reference_title: "Anomalous Epithelial Variations and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease."
supports: PARTIAL
snippet: Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown.
explanation: This study notes the involvement of epithelial cells in COPD but states that mechanisms remain unknown, partially supporting the role of epithelial cells in airflow obstruction.
- reference: PMID:38625125
reference_title: "Revisiting airway epithelial dysfunction and mechanisms in chronic obstructive pulmonary disease: the role of mitochondrial damage."
supports: SUPPORT
snippet: Chronic exposure to environmental hazards causes airway epithelial dysfunction, primarily impaired physical barriers, immune dysfunction, and repair or regeneration. Impairment of airway epithelial function subsequently leads to exaggerated airway inflammation and remodeling, the main features of chronic obstructive pulmonary disease (COPD).
explanation: This study supports the statement by highlighting the role of epithelial dysfunction, inflammation, and remodeling in COPD pathophysiology.
- name: Chronic Inflammation
description: Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.
cell_types:
- preferred_term: Neutrophil
term:
id: CL:0000775
label: neutrophil
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: T-lymphocyte
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
- preferred_term: neutrophil degranulation
term:
id: GO:0043312
label: neutrophil degranulation
locations:
- preferred_term: bronchus
term:
id: UBERON:0002185
label: bronchus
- preferred_term: alveolus of lung
term:
id: UBERON:0002299
label: alveolus of lung
evidence:
- reference: PMID:17305517
reference_title: "Inflammatory cells and chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Neutrophils and macrophages have been implicated in this process; they release proteolytic enzymes and generate oxidants, which cause tissue damage, as well as cytokines and chemokines, which can potentiate inflammation and trigger an immune response.
explanation: The literature describes the involvement of neutrophils, macrophages, and T-lymphocytes in the inflammatory process associated with COPD, supporting the notion of persistent irritation and chronic inflammation.
- reference: PMID:24507838
reference_title: "Cellular and molecular mechanisms of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: This inflammation is characterized by increased numbers of alveolar macrophages, neutrophils, and T lymphocytes, which are recruited from the circulation.
explanation: This article further substantiates the involvement of these cell types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of COPD, linking them to chronic inflammation.
- reference: PMID:38035712
reference_title: "Characteristics of inflammatory phenotypes in patients with chronic obstructive pulmonary disease: a cross-sectional study."
supports: SUPPORT
snippet: In this study, we found that neutrophilic phenotype (NP, 58.0%) was the most common airway inflammation phenotype in patients with COPD, followed by mixed granulocytic phenotype (MGP, 32.6%).
explanation: The study indicates that neutrophils are predominant in COPD, supporting the statement about chronic inflammation.
- reference: PMID:38891820
reference_title: "Macrophage Polarization and Functions in Pathogenesis of Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: Recent multiomics-based evidence suggests that the plasticity of alveolar macrophages contributes to the onset and progression of COPD through the coordinated modulation of numerous transcription factors.
explanation: The article highlights the role of macrophages in the pathogenesis and progression of COPD, thus supporting the statement.
- reference: PMID:11993785
reference_title: "Pathology and pathophysiology of chronic obstructive pulmonary disease."
supports: PARTIAL
snippet: The characteristic changes in the central airways include inflammatory cellular infiltration into the airway wall and mucous gland enlargement.
explanation: This reference provides a broader overview of the pathological changes in COPD, mentioning inflammatory cells but not specifically detailing the involvement of neutrophils, macrophages, and T-lymphocytes.
- name: Airway Remodeling
description: Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.
cell_types:
- preferred_term: Smooth Muscle Cell
term:
id: CL:0000192
label: smooth muscle cell
biological_processes:
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
- preferred_term: fibrosis
description: Excessive deposition of connective tissue
locations:
- preferred_term: bronchus
term:
id: UBERON:0002185
label: bronchus
- preferred_term: small airway
description: Terminal and respiratory bronchioles
evidence:
- reference: PMID:20500603
reference_title: "Pathological airway remodelling in inflammation."
supports: SUPPORT
snippet: Moreover, airway remodelling occurs not only in asthma but also in several pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and systemic sclerosis.
explanation: The statement aligns with the mentioned literature which notes airway remodeling as part of chronic obstructive pulmonary disease.
- reference: PMID:30257694
reference_title: "Roles of airway smooth muscle dysfunction in chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Multiple dysfunctions of ASM contribute to modulating airway responses to stimuli, remodeling, and fibrosis, as well as influence the compliance of lungs.
explanation: The statement is supported as this literature highlights the role of airway smooth muscle cells in airway remodeling and fibrosis in COPD.
- reference: PMID:15347849
reference_title: "Differences in airway remodeling between asthma and chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD.
explanation: The literature supports the statement by confirming the involvement of smooth muscle cells and structural changes in the airways in COPD.
- name: Alveolar Destruction
description: Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.
cell_types:
- preferred_term: Alveolar Macrophage
term:
id: CL:0000583
label: alveolar macrophage
biological_processes:
- preferred_term: proteolysis
term:
id: GO:0006508
label: proteolysis
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
locations:
- preferred_term: alveolus of lung
term:
id: UBERON:0002299
label: alveolus of lung
- preferred_term: lung parenchyma
term:
id: UBERON:0008946
label: lung parenchyma
evidence:
- reference: PMID:11993785
reference_title: "Pathology and pathophysiology of chronic obstructive pulmonary disease."
supports: PARTIAL
snippet: In the lung parenchyma, emphysema defined as alveolar destruction and airspace enlargement is present.
explanation: While the reference supports alveolar destruction as part of COPD's pathophysiology, it does not mention alveolar macrophages specifically.
- reference: PMID:29433833
reference_title: "Macrophage phagocytosis cracking the defect code in COPD."
supports: PARTIAL
snippet: In inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), despite their increased numbers, macrophages demonstrate significantly reduced phagocytic capacity of bacteria and apoptotic cells.
explanation: The macrophages' role in the pathophysiology of COPD is discussed, focusing on their reduced phagocytic capacity rather than direct alveolar destruction.
- reference: PMID:32493486
reference_title: "Alveolar lipids in pulmonary disease. A review."
supports: PARTIAL
snippet: External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD).
explanation: The role of alveolar macrophages (responsible for the degradation of surfactant) in the development of COPD is mentioned, but no direct link to alveolar destruction.
- reference: PMID:24707174
reference_title: "The role of microparticles in chronic obstructive pulmonary disease."
supports: PARTIAL
snippet: 'There are eight types of EMPs which are defined by the presence of different endothelial markers on the cell membrane: vascular endothelial-cadherin; platelet endothelial cell adhesion molecule; melanoma cell adhesion molecule; E-selectin; CD51; CD105; von Willebrand factor; and CD143 EMPs.'
explanation: The reference discusses endothelial injury and microparticles in COPD, which may indirectly relate to alveolar destruction, but does not directly address it or the role of alveolar macrophages.
- name: Oxidative Stress and Mitochondrial Dysfunction
description: Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.
cell_types:
- preferred_term: airway epithelial cell
term:
id: CL:0002368
label: respiratory tract epithelial cell
- preferred_term: Alveolar Macrophage
term:
id: CL:0000583
label: alveolar macrophage
biological_processes:
- preferred_term: response to oxidative stress
term:
id: GO:0006979
label: response to oxidative stress
- preferred_term: mitochondrion organization
term:
id: GO:0007005
label: mitochondrion organization
- preferred_term: mitophagy
term:
id: GO:0000422
label: autophagy of mitochondrion
locations:
- preferred_term: bronchus
term:
id: UBERON:0002185
label: bronchus
- preferred_term: alveolus of lung
term:
id: UBERON:0002299
label: alveolus of lung
notes: Reduced Nrf2 and SIRT1 activity diminishes antioxidant capacity; mitochondrial ROS activates NLRP3 inflammasome.
- name: Mucus Hypersecretion
description: Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.
cell_types:
- preferred_term: goblet cell
term:
id: CL:0000160
label: goblet cell
- preferred_term: club cell
term:
id: CL:0000158
label: club cell
biological_processes:
- preferred_term: mucus secretion
term:
id: GO:0070254
label: mucus secretion
- preferred_term: cilium movement
term:
id: GO:0003341
label: cilium movement
locations:
- preferred_term: bronchus
term:
id: UBERON:0002185
label: bronchus
- preferred_term: small airway
description: Terminal and respiratory bronchioles
notes: MUC5AC/MUC5B overexpression and club-to-goblet transdifferentiation impair airway clearance.
- name: NLRP3 Inflammasome Activation
description: Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1β/IL-18 release.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: airway epithelial cell
term:
id: CL:0002368
label: respiratory tract epithelial cell
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
cellular_components:
- preferred_term: NLRP3 inflammasome complex
term:
id: GO:0072559
label: NLRP3 inflammasome complex
locations:
- preferred_term: bronchus
term:
id: UBERON:0002185
label: bronchus
- preferred_term: alveolus of lung
term:
id: UBERON:0002299
label: alveolus of lung
notes: PM2.5 and cigarette smoke synergize to activate NLRP3/caspase-1 signaling.
- name: Cellular Senescence
description: Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.
cell_types:
- preferred_term: airway epithelial cell
term:
id: CL:0002368
label: respiratory tract epithelial cell
- preferred_term: fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: cellular senescence
term:
id: GO:0090398
label: cellular senescence
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
locations:
- preferred_term: lung
term:
id: UBERON:0002048
label: lung
notes: SASP factors include IL-6, CXCL8, and MMPs; senolytic therapies are under investigation.
phenotypes:
- category: Respiratory
name: Dyspnea
frequency: VERY_FREQUENT
diagnostic: true
evidence:
- reference: PMID:28277858
reference_title: "Pathophysiology of dyspnea in COPD."
supports: SUPPORT
snippet: Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival.
explanation: The literature supports that dyspnea is a common symptom in COPD and is frequently observed in patients, confirming its categorization as a respiratory phenotype with diagnostic importance.
- reference: PMID:35698999
reference_title: "The prevalence and assessment of pain and dyspnoea in acute exacerbations of COPD: A systematic review."
supports: SUPPORT
snippet: Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively.
explanation: This study highlights the high prevalence of dyspnea in patients with COPD, further supporting its status as a very frequent respiratory phenotype.
- reference: PMID:34972922
reference_title: "Exhaled Breath Condensate and Dyspnea in COPD."
supports: SUPPORT
snippet: Up to date research has shown a positive correlation between the elevated levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while others present ambiguous results
explanation: The correlation between dyspnea and COPD is reinforced by the positive association found with certain markers in exhaled breath condensate.
sequelae:
- target: Exercise Intolerance
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
- category: Respiratory
name: Chronic Cough
frequency: VERY_FREQUENT
diagnostic: true
evidence:
- reference: PMID:29881269
reference_title: "Chronic cough as a novel phenotype of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Compared with patients without chronic cough, those with chronic cough exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD, more severe dyspnea, and worse QoL.
explanation: The study identifies chronic cough as a common and significant phenotype in COPD patients, indicating its very frequent occurrence and diagnostic importance.
- reference: PMID:31740261
reference_title: "\"Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.\"."
supports: SUPPORT
snippet: COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. This review will discuss the old and new concepts for the different types of COPD phenotypes.
explanation: The statement mentions the heterogeneity of COPD with multiple phenotypes, which could include phenotypes like chronic cough.
notes: Often productive of mucus
phenotype_term:
preferred_term: Chronic Cough
term:
id: HP:0034315
label: Chronic cough
- category: Respiratory
name: Sputum Production
frequency: VERY_FREQUENT
evidence:
- reference: PMID:22753831
reference_title: "Chronic cough and sputum production: a clinical COPD phenotype?"
supports: SUPPORT
snippet: 'Chronic cough and sputum production: a clinical COPD phenotype?'
explanation: The title of the article itself suggests that sputum production is recognized as a phenotype of COPD.
- reference: PMID:23204254
reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
explanation: Chronic bronchitis, which involves overproduction and hypersecretion of mucus, is described as a common phenomenon in COPD, indicating sputum production is a frequent COPD phenotype.
notes: Mucus is often difficult to expectorate
phenotype_term:
preferred_term: Sputum Production
term:
id: HP:0033709
label: Increased sputum production
- category: Respiratory
frequency: FREQUENT
name: Wheezing
notes: Due to airflow obstruction
evidence:
- reference: PMID:33302722
reference_title: "Is the Symptom of Cough in Chronic Obstructive Pulmonary Disease Important?"
supports: SUPPORT
snippet: The clinical symptoms of this disease include progressive dyspnea, cough, expectoration, and wheezing, among others.
explanation: The abstract mentions wheezing as one of the clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD).
- reference: PMID:11963614
reference_title: "Breathless."
supports: SUPPORT
snippet: Remember, all that wheezes is not asthma; therefore, providers in this case had to determine if the patient was suffering something such as anaphylaxis, asthma, bronchitis, pneumonia or even congestive heart failure (CHF).
explanation: The abstract indicates that wheezing can be a symptom of various conditions, including COPD-related bronchospasm.
- reference: PMID:2404712
reference_title: "Pathology of chronic airflow obstruction."
supports: SUPPORT
snippet: Increased airways reactivity is present in 15 to 70 percent of patients with chronic airflow obstruction.
explanation: The abstract discusses increased airway reactivity, which is related to wheezing, in patients with chronic airflow obstruction, including COPD.
phenotype_term:
preferred_term: Wheezing
term:
id: HP:0030828
label: Wheezing
- category: Respiratory
frequency: OCCASIONAL
name: Barrel Chest
notes: Due to hyperinflation of the lungs
evidence:
- reference: PMID:25159007
reference_title: "Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment."
supports: PARTIAL
snippet: Lung hyperinflation is highly prevalent in patients with chronic obstructive pulmonary disease and occurs across the continuum of the disease.
explanation: The reference supports the association of lung hyperinflation with COPD but does not specifically mention 'Barrel Chest' or its frequency.
- reference: PMID:34972922
reference_title: "Exhaled Breath Condensate and Dyspnea in COPD."
supports: PARTIAL
snippet: Attempts to connect the products of the analysis of the EBC with the clinical manifestations of COPD such as dyspnea are scarce.
explanation: The reference discusses the clinical manifestations of COPD but does not specifically mention 'Barrel Chest' or its frequency.
- reference: PMID:23204254
reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
supports: NO_EVIDENCE
snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
explanation: The reference discusses chronic bronchitis in COPD but does not mention 'Barrel Chest' or its frequency.
- category: Respiratory
frequency: OCCASIONAL
name: Respiratory Failure
sequelae:
- target: Hypoxemia
- target: Hypercapnia
evidence:
- reference: PMID:14621114
reference_title: "Respiratory failure in chronic obstructive pulmonary disease."
supports: REFUTE
snippet: Respiratory failure is still an important complication of chronic obstructive pulmonary disease (COPD) and hospitalisation with an acute episode being a poor prognostic marker.
explanation: The reference indicates that respiratory failure is an important and common complication of COPD, not an occasional one.
- reference: PMID:38692758
reference_title: "Targeting Hypercapnia in Chronic Lung Disease and Obesity Hypoventilation: Benefits and Challenges."
supports: REFUTE
snippet: Hypoventilation is a complication that is not uncommon in chronic obstructive pulmonary disease and calls for both medical treatment of the underlying disease and, frequently, noninvasive ventilation either during exacerbations requiring hospitalization or in a chronic state in the patient at home.
explanation: The reference suggests that hypoventilation, which can lead to respiratory failure, is not uncommon in COPD.
phenotype_term:
preferred_term: Respiratory Failure
term:
id: HP:0002878
label: Respiratory failure
- category: Systemic
frequency: FREQUENT
name: Fatigue
evidence:
- reference: PMID:33998496
reference_title: "Fatigue: A neglected symptom of COPD."
supports: SUPPORT
snippet: 'Fatigue: A neglected symptom of COPD.'
explanation: The title itself indicates that fatigue is a recognized symptom of COPD.
- reference: PMID:31729154
reference_title: "Fatigue and health-related quality of life among patients with chronic obstructive pulmonary disease in China."
supports: SUPPORT
snippet: Fatigue is an important yet ignored symptom of chronic obstructive pulmonary disease (COPD).
explanation: This reference acknowledges fatigue as an important symptom of COPD, supporting its frequent occurrence.
- reference: PMID:24874124
reference_title: "The systemic nature of chronic lung disease."
supports: SUPPORT
snippet: Symptoms in COPD do not solely arise from the degree of airflow obstruction as exercise limitation is compounded by the specific secondary manifestations of the disease including skeletal muscle impairment, osteoporosis, mood disturbance, anemia, and hormonal imbalance.
explanation: While this reference does not mention fatigue explicitly, it discusses systemic manifestations of COPD, implying the systemic nature of the disease.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
- category: Systemic
frequency: OCCASIONAL
name: Weight Loss
notes: More common in advanced disease
evidence:
- reference: PMID:12406664
reference_title: "Weight loss in chronic obstructive pulmonary disease. Mechanisms and implications."
supports: SUPPORT
snippet: Weight loss occurs frequently in patients with chronic obstructive pulmonary disease (COPD).
explanation: The literature states that weight loss is a common phenomenon in COPD patients, which supports the statement that weight loss is a systemic issue in COPD, more common in advanced disease.
- reference: PMID:18415812
reference_title: "COPD as a systemic disease."
supports: SUPPORT
snippet: These include unintentional weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others.
explanation: This reference mentions unintentional weight loss as one of the systemic effects of COPD, supporting the statement.
- reference: PMID:36922031
reference_title: "Contemporary Concise Review 2022: Chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more.
explanation: The mention of cachexia (underweight) as a comorbidity in COPD patients aligns with the statement about weight loss being more common in advanced disease.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Cardiovascular
name: Exercise Intolerance
frequency: FREQUENT
phenotype_term:
preferred_term: Exercise Intolerance
term:
id: HP:0003546
label: Exercise intolerance
- category: Respiratory
name: Hypoxemia
frequency: FREQUENT
phenotype_term:
preferred_term: Hypoxemia
term:
id: HP:0012418
label: Hypoxemia
- category: Respiratory
name: Hypercapnia
frequency: FREQUENT
phenotype_term:
preferred_term: Hypercapnia
term:
id: HP:0012416
label: Hypercapnia
biochemical:
- name: Arterial Blood Gases
presence: Altered
notes: May show hypoxemia and hypercapnia.
evidence:
- reference: PMID:21812941
reference_title: "Explained variance for blood gases in a population with COPD."
supports: PARTIAL
snippet: The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients.
explanation: The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions.
- reference: PMID:34756790
reference_title: "Arterial Blood Gas and Rotational Thromboelastometry Parameters in Healthy Rescuers Incidentally Exposed to Nitroglycerin, Nitrogen Compounds, and Combustion Products."
supports: SUPPORT
snippet: Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation.
explanation: The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts.
- reference: PMID:25119324
reference_title: "Arterialised earlobe capillary blood gases in the COPD population."
supports: SUPPORT
snippet: The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD).
explanation: While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases.
- reference: PMID:18044093
reference_title: "Respiratory disorders during sleep in chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Patients with COPD may show slow, progressive deteriorations in arterial blood gases during the night, particularly during rapid eye movement (REM) sleep. This is mainly due to hypoventilation... The severity of gas exchanges alterations is proportional to the degree of impairment of diurnal pulmonary function tests, particularly of partial pressure of oxygen (PaO2) and of carbon dioxide (PaCO2) in arterial blood...
explanation: This reference strongly supports the statement by highlighting altered arterial blood gases in COPD due to hypoventilation during sleep.
- name: C-Reactive Protein (CRP)
presence: Elevated
context: General inflammation and exacerbations.
evidence:
- reference: PMID:23206444
reference_title: "Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis."
supports: SUPPORT
snippet: Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47).
explanation: This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD.
- reference: PMID:24313775
reference_title: "Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available.
explanation: The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts.
- reference: PMID:24102428
reference_title: "Serum angiopoietin-2 and CRP levels during COPD exacerbations."
supports: SUPPORT
snippet: Serum CRP levels were also significantly higher on D1 compared to D7 (p < 0.001).
explanation: The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement.
- reference: PMID:26595735
reference_title: "Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: A number of studies support the conclusion that immune dysfunction leads to exacerbations and disease severity in COPD.
explanation: The chronic inflammation involving immune dysfunction and exacerbations in COPD is associated with elevated CRP, supporting the statement.
- reference: PMID:37082823
reference_title: "Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome."
supports: SUPPORT
snippet: Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and granulocyte colony stimulating factor (G-CSF) were higher in participants with OVS and COPD compared with healthy controls and participants with OSA.
explanation: Elevated hs-CRP in COPD patients relative to healthy controls supports the general inflammation and exacerbation context.
genetic:
- name: SERPINA1
association: Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.
notes: Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease imbalance and emphysema.
evidence:
- reference: PMID:32800189
reference_title: "Alpha-1 Antitrypsin Deficiency Associated COPD."
supports: SUPPORT
snippet: Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described.
explanation: The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement.
- reference: PMID:35104244
reference_title: "Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease."
supports: SUPPORT
snippet: Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease.
explanation: The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD.
- reference: PMID:36630963
reference_title: "Capturing the conversion of the pathogenic alpha-1-antitrypsin fold by ATF6 enhanced proteostasis."
supports: SUPPORT
snippet: Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD).
explanation: The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement.
- name: MMP12
association: Matrix metalloproteinase-12 contributes to emphysema development.
notes: Macrophage-derived protease that degrades elastin and extracellular matrix.
- name: NLRP3
association: Inflammasome activation contributes to chronic inflammation.
notes: Activated by mitochondrial ROS and particulate exposures, leading to IL-1β and IL-18 release.
- name: TNF
association: Tumor necrosis factor mediates systemic and airway inflammation.
notes: Key pro-inflammatory cytokine in COPD pathogenesis.
- name: IL1B
association: Interleukin-1 beta drives inflammatory signaling.
notes: Product of NLRP3 inflammasome activation.
- name: IL6
association: Interleukin-6 contributes to systemic inflammation.
notes: Elevated in serum and associated with COPD comorbidities.
- name: NFE2L2
association: Nrf2 transcription factor regulates antioxidant defense.
notes: Reduced activity impairs response to oxidative stress in COPD.
environmental:
- name: Smoking
notes: Primary risk factor for development and progression.
evidence:
- reference: PMID:30810540
reference_title: "ROLE OF GENETIC SUSCEPTIBILITY IN NICOTINE ADDICTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE."
supports: SUPPORT
snippet: Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD.
explanation: This clearly identifies smoking as a major risk factor for COPD development.
- reference: PMID:31759959
reference_title: "Cardiovascular Risk in COPD: Deciphering the Contribution of Tobacco Smoking."
supports: SUPPORT
snippet: The observation that COPD is an independent risk factor for cardiovascular disease (CVDs) comes from comparisons between smokers with COPD and smokers without COPD.
explanation: This snippet highlights the relationship between smoking, COPD, and other health issues, indirectly supporting smoking as a risk factor for COPD.
- reference: PMID:28933915
reference_title: "Airway Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease: Role of Cigarette Smoke Exposure."
supports: SUPPORT
snippet: The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD).
explanation: Directly states that cigarette smoke is the primary risk factor for COPD development.
- reference: PMID:18303418
reference_title: "Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality."
supports: SUPPORT
snippet: Approximately one-quarter of smokers can be affected by clinically significant chronic obstructive pulmonary disease. ... Smokers may reduce their risk of developing chronic obstructive pulmonary disease by physical activity and increase their survival by smoking reduction.
explanation: This supports the statement by highlighting the prevalence of COPD among smokers and the role of smoking in disease progression.
- reference: PMID:37429033
reference_title: "Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life."
supports: SUPPORT
snippet: 'Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life.'
explanation: This implies that smoking is a risk factor in the development of COPD.
exposure_term:
preferred_term: Tobacco smoking exposure
term:
id: ECTO:6000029
label: exposure to tobacco smoking
- name: Air Pollution
notes: Exposure to pollutants can exacerbate symptoms.
evidence:
- reference: PMID:33542053
reference_title: "Personal exposure to air pollution and respiratory health of COPD patients in London."
supports: SUPPORT
snippet: Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health.
explanation: This study found that exposure to various air pollutants adversely affects the health of COPD patients, supporting the idea that air pollution exacerbates COPD symptoms.
- reference: PMID:25673984
reference_title: "COPD: balancing oxidants and antioxidants."
supports: SUPPORT
snippet: The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses.
explanation: This reference discusses environmental factors, including pollutants, that contribute to oxidative stress and inflammation in COPD, thus supporting the statement.
- reference: PMID:37068517
reference_title: "Chronic Obstructive Pulmonary Disease and Work: The Continuing Narrative."
supports: SUPPORT
snippet: Harmful inhaled workplace exposures can contribute to the development of chronic obstructive pulmonary disease (COPD).
explanation: This statement supports the environmental influence on COPD, including air pollutants, as a risk factor.
- reference: PMID:16916323
reference_title: "Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution."
supports: SUPPORT
snippet: Evidence from epidemiological studies finding consistent associations between air pollution and various outcomes (respiratory symptoms, reduced lung function, chronic bronchitis and mortality), has suggested that outdoor air pollution is a contributing cause of morbidity and mortality.
explanation: This reference directly links air pollution to exacerbation and pathogenesis of COPD, supporting the statement.
- reference: PMID:27751401
reference_title: "Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action."
supports: SUPPORT
snippet: We focus on the major constituents of air pollutants and their impacts on chronic respiratory diseases.
explanation: This review highlights the detrimental effects of air pollution on respiratory health, particularly in the discussion on chronic respiratory diseases such as COPD.
exposure_term:
preferred_term: Air pollution exposure
term:
id: ECTO:8000036
label: exposure to air pollution
- name: Occupational Dust and Chemicals
notes: Long-term exposure increases risk.
evidence:
- reference: PMID:11964759
reference_title: "Chronic obstructive lung diseases and occupational exposure."
supports: SUPPORT
snippet: occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease
explanation: The abstract confirms that occupational exposure to dusts, chemicals, and gases is a well-supported risk factor for chronic obstructive pulmonary disease.
- reference: PMID:20535848
reference_title: "Lung function loss associated with occupational dust exposure in metal smelting."
supports: SUPPORT
snippet: Lung function loss associated with occupational dust exposure in metal smelting
explanation: This study provides evidence of lung function loss due to occupational dust exposure, supporting the assertion that long-term exposure to such environmental factors increases the risk of chronic obstructive pulmonary disease.
- reference: PMID:23361196
reference_title: "Long-term respiratory health effects in textile workers."
supports: SUPPORT
snippet: Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD)
explanation: The abstract discusses the recognized contribution of workplace exposures, including textile dust, to chronic obstructive pulmonary disease.
- reference: PMID:24278358
reference_title: "Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis."
supports: SUPPORT
snippet: Occupational inhalative exposure to bg-dust was associated with a statistically significant decreased FEV1 and FEV1/FVC revealing airway obstruction consistent with COPD
explanation: The meta-analysis presented indicates a significant association between occupational exposure to inorganic dust and the development of chronic obstructive pulmonary disease.
- reference: PMID:35409627
reference_title: "Environmental Substances Associated with Chronic Obstructive Pulmonary Disease-A Scoping Review."
supports: SUPPORT
snippet: Pesticides in general and especially organophosphate and carbamate insecticides... showed an association, and cadmium (Cd), chromium (Cr and CrVI), arsenic (As), and diisocyanates, a possible association with COPD
explanation: The scoping review identifies several environmental substances, including chemicals associated with occupational exposure, that have a strong or possible association with chronic obstructive pulmonary disease.
exposure_term:
preferred_term: Occupational dust exposure
term:
id: ECTO:7000001
label: exposure to dust
treatments:
- name: Smoking Cessation
description: Stopping smoking to slow disease progression and improve outcomes.
evidence:
- reference: PMID:25496790
reference_title: "[Smoking cessation in smokers with chronic obstructive pulmonary disease]."
supports: SUPPORT
snippet: Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality.
explanation: The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.
- reference: PMID:19811377
reference_title: "Defining disease modification in chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions.
explanation: The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.
- reference: PMID:11935838
reference_title: "Minimizing the impact of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: The most important intervention is smoking cessation.
explanation: The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.
- reference: PMID:27576232
reference_title: "Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: Smoking cessation is the only intervention shown to slow disease progression.
explanation: The reference clearly supports the claim that smoking cessation can slow disease progression and improve outcomes for COPD patients.
treatment_term:
preferred_term: behavioral counseling
term:
id: MAXO:0000077
label: behavioral counseling
- name: Bronchodilators
description: Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).
evidence:
- reference: PMID:29794201
reference_title: "Clinical Pharmacology of Bronchodilator Medications."
supports: SUPPORT
snippet: Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life.
explanation: The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.
- reference: PMID:27576232
reference_title: "Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted.
explanation: This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.
- reference: PMID:28757318
reference_title: "New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler."
supports: SUPPORT
snippet: Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease.
explanation: This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.
treatment_term:
preferred_term: bronchodilator therapy
term:
id: MAXO:0000316
label: bronchodilator therapy
- name: Inhaled Corticosteroids
description: Reduce airway inflammation and frequency of exacerbations.
evidence:
- reference: PMID:20102305
reference_title: "Inhaled corticosteroids in chronic obstructive pulmonary disease: a review."
supports: PARTIAL
snippet: Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD.
explanation: While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.
- reference: PMID:37348121
reference_title: "Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook."
supports: PARTIAL
snippet: Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD
explanation: ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.
- reference: PMID:29938633
reference_title: "[Treatment of stable chronic obstructive pulmonary disease]."
supports: SUPPORT
snippet: The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids.
explanation: The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.
- reference: PMID:30846476
reference_title: "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019."
supports: SUPPORT
snippet: Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations.
explanation: The new evidence indicates that ICS are effective in reducing exacerbations, supporting their role in treatment.
treatment_term:
preferred_term: respiratory tract agent therapy
term:
id: MAXO:0000312
label: respiratory tract agent therapy
- name: Phosphodiesterase-4 Inhibitors
description: Reduce inflammation and relax airways.
evidence:
- reference: PMID:15699784
reference_title: "Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease."
supports: SUPPORT
snippet: Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils.
explanation: The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.
- reference: PMID:20649375
reference_title: "Roflumilast for the treatment of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress.
explanation: Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.
- reference: PMID:34731461
reference_title: "Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure.
explanation: This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.
- reference: PMID:32361678
reference_title: "Kinase inhibitors in the treatment of obstructive pulmonary diseases."
supports: SUPPORT
snippet: Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease.
explanation: This reference supports the role of PDE inhibitors, specifically kinase inhibitors, in reducing inflammation in COPD.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Oxygen Therapy
description: Long-term oxygen use for patients with severe chronic hypoxemia.
evidence:
- reference: PMID:24461631
reference_title: "Continuous home oxygen therapy."
supports: SUPPORT
snippet: This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure.
explanation: The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.
- reference: PMID:37353334
reference_title: "Oxygen Therapy in COPD."
supports: SUPPORT
snippet: Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD.
explanation: This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.
- reference: PMID:19462352
reference_title: "End stage chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD.
explanation: This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.
treatment_term:
preferred_term: artificial respiration
term:
id: MAXO:0000503
label: artificial respiration
- name: Pulmonary Rehabilitation
description: Exercise training, education, and support to improve quality of life and physical conditioning.
evidence:
- reference: PMID:29526182
reference_title: "Pulmonary Rehabilitation and Exercise Training in Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD.
explanation: The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support.
- reference: PMID:34338012
reference_title: "Management of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available.
explanation: This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.
- reference: PMID:34955635
reference_title: "Self-Efficacy Intervention Programs in Patients with Chronic Obstructive Pulmonary Disease: Narrative Review."
supports: SUPPORT
snippet: The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD.
explanation: This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.
- reference: PMID:24874124
reference_title: "The systemic nature of chronic lung disease."
supports: SUPPORT
snippet: Pulmonary rehabilitation targets the systemic manifestations of COPD, the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid treatment.
explanation: This reference supports the statement by indicating that pulmonary rehabilitation addresses systemic issues in COPD and implies improvement in quality of life and physical conditioning.
- reference: PMID:24507849
reference_title: "Pulmonary rehabilitation."
supports: SUPPORT
snippet: The main objective of pulmonary rehabilitation is to restore muscle function and exercise tolerance, reverse other nonrespiratory consequences of the disease, and help patients to self-manage chronic obstructive pulmonary disease and its exacerbations and symptoms.
explanation: This reference supports the statement by detailing the benefits of pulmonary rehabilitation, including exercise training, education, and support, to improve quality of life and physical conditioning.
treatment_term:
preferred_term: physical therapy
term:
id: MAXO:0000011
label: physical therapy
- name: Lung Volume Reduction Surgery
description: Surgical removal of damaged lung tissue for severe emphysema.
evidence:
- reference: PMID:22189668
reference_title: "Lung volume reduction for advanced emphysema: surgical and bronchoscopic approaches."
supports: SUPPORT
snippet: Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema.
explanation: The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.
- reference: PMID:33926668
reference_title: "Alpha(1)-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery."
supports: SUPPORT
snippet: As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema.
explanation: The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.
- reference: PMID:31145187
reference_title: "Emerging Interventional Pulmonary Therapies for Chronic Obstructive Pulmonary Disease."
supports: SUPPORT
snippet: 'Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity.'
explanation: The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
- name: Lung Transplantation
description: Considered in end-stage COPD with severe impairment.
evidence:
- reference: PMID:17240617
reference_title: "Transplantation in chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD.
explanation: This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.
- reference: PMID:31375190
reference_title: "Palliative Care Approach to Chronic Diseases: End Stages of Heart Failure, Chronic Obstructive Pulmonary Disease, Liver Failure, and Renal Failure."
supports: SUPPORT
snippet: End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states.
explanation: The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.
- reference: PMID:36050206
reference_title: "The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease.
explanation: This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD.
- reference: PMID:23248802
reference_title: "A brief review of chronic obstructive pulmonary disease."
supports: SUPPORT
snippet: Chronic obstructive pulmonary disease...treated by lung transplantation.
explanation: This abstract explicitly mentions the use of lung transplantation for individuals with very severe COPD.
treatment_term:
preferred_term: organ transplantation
term:
id: MAXO:0010039
label: organ transplantation
- name: Mucolytic Therapy
description: N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.
notes: Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression and mucus rheology.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
- name: Macrolide Antibiotics
description: Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.
notes: Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial effects.
treatment_term:
preferred_term: antibiotic therapy
term:
id: NCIT:C15620
label: Antibiotic Therapy
- name: Biologic Therapies
description: Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.
notes: Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33 and anti-TSLP under investigation.
treatment_term:
preferred_term: biologic therapy
term:
id: NCIT:C15262
label: Immunotherapy
review_notes: COPD is characterized by progressive airflow obstruction that is not fully reversible. Key respiratory symptoms include dyspnea, chronic cough, sputum production, and wheezing. As the disease progresses, patients may develop signs of lung hyperinflation (barrel chest) and are at risk for respiratory failure. Systemic effects like fatigue and weight loss are also common, particularly in advanced disease.
disease_term:
preferred_term: chronic obstructive pulmonary disease
term:
id: MONDO:0005002
label: chronic obstructive pulmonary disease
classifications:
harrisons_chapter:
- classification_value: respiratory system disorder
- classification_value: obstructive lung disease
references:
- reference: DOI:10.1136/thorax-2023-220455
title: Lower airway microbiota in COPD and healthy controls
findings: []
- reference: DOI:10.1164/rccm.202306-1060oc
title: Accelerated Lung Function Decline and Mucus–Microbe Evolution in Chronic Obstructive Pulmonary Disease
findings: []
- reference: DOI:10.1183/23120541.00177-2024
title: What every clinician should know about inflammation in COPD
findings: []
- reference: DOI:10.3389/fimmu.2024.1404615
title: Inflammation mechanism and research progress of COPD
findings: []
- reference: DOI:10.3390/ijms25147780
title: Cellular and Molecular Biology of Mitochondria in Chronic Obstructive Pulmonary Disease
findings: []
- reference: DOI:10.3390/ijms26052184
title: 'Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions'
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Chronic Obstructive Pulmonary Disease (COPD) - MONDO ID: MONDO:0005002 - Category: Complex
Pathophysiology description (current understanding, 2023–2024) COPD is a heterogeneous chronic inflammatory lung disease characterized by persistent airflow limitation arising from small airway disease (airway wall thickening, fibrosis, mucus plugging) and parenchymal destruction (emphysema). A pathogenic triad—chronic inflammation, protease–antiprotease imbalance, and oxidative stress—interacts with cellular senescence, mitochondrial dysfunction, mucociliary failure, inflammasome activation, dysbiosis, and autoimmunity to drive progression from early small-airway pathology to emphysema and chronic bronchitis (mucus hypersecretion) phenotypes (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). Oxidative stress and impaired mitochondrial quality control amplify inflammation and inflammasome signaling; senescent epithelial, fibroblast, and immune cells propagate a SASP cytokine milieu; excess neutrophil and macrophage proteases degrade elastin and extracellular matrix; airway epithelial remodeling increases MUC5AC/MUC5B and impairs mucociliary transport; and airway microbiome interactome disturbance (loss of antagonistic interactions) correlates with neutrophilic inflammation, symptoms, and exacerbation risk (li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10).
| Mechanistic axis | Key molecules (HGNC symbols) | Principal cells (CL terms) | Subcellular / compartment | Evidence highlights (1–2 sentences) | Sources (DOI + year) |
|---|---|---|---|---|---|
| Chronic inflammation & endotypes | TNF, IL1B, IL6, CXCL8, IL17A, IL5 | Neutrophil (CL), Alveolar macrophage (CL), CD8+ T cell (CL), Eosinophil (CL) | Cytokine signaling / NF-κB (cytosol → nucleus) | Persistent mixed neutrophilic/eosinophilic airway inflammation defines heterogeneous endotypes; blood/sputum eosinophils predict ICS response and guide biologics (xu2024inflammationmechanismand pages 7-8, wechsler2024whateveryclinician pages 11-12). | 10.3389/fimmu.2024.1404615 (2024); 10.1183/23120541.00177-2024 (2024) |
| Protease–antiprotease imbalance | ELANE (neutrophil elastase), MMP12, SERPINA1 (A1AT) | Neutrophil (CL), Macrophage (CL) | Extracellular matrix / elastin degradation | Excess neutrophil proteases and MMPs degrade ECM and elastin promoting emphysema; A1AT deficiency exacerbates proteolytic damage (wechsler2024whateveryclinician pages 11-12, xu2024inflammationmechanismand pages 7-8). | 10.1183/23120541.00177-2024 (2024); 10.3389/fimmu.2024.1404615 (2024) |
| Oxidative stress & mitochondrial dysfunction | NFE2L2 (Nrf2), SOD2, SIRT1, NOX family | Airway epithelial cells (CL), Alveolar macrophage (CL) | Mitochondria, ROS, impaired mitophagy | Cigarette smoke–driven mitochondrial ROS and defective mitophagy amplify inflammation and may impair steroid responsiveness; mitochondria-targeted antioxidants are proposed (li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). | 10.3390/ijms25147780 (2024); 10.3389/fimmu.2024.1404615 (2024) |
| Cellular senescence & SASP | CDKN2A (p16), CDKN1A (p21), IL6, MMPs | Epithelial cells (CL), Fibroblasts (CL), Macrophages (CL) | Nuclear DNA damage, SASP secretion | Senescent lung cells secrete SASP (eg, IL‑6, CXCL8, MMPs) driving chronic inflammation and remodeling; senolytic/senomorphic strategies show preclinical promise (wechsler2024whateveryclinician pages 11-12, xu2024inflammationmechanismand pages 7-8). | 10.1183/23120541.00177-2024 (2024); 10.3389/fimmu.2024.1404615 (2024) |
| Mucus hypersecretion / mucociliary dysfunction | MUC5AC, MUC5B, EGFR | Goblet cell (CL), Club cell (CL), Ciliated cell (CL) | Secreted mucin polymers / apical mucus layer | MUC5AC/MUC5B overexpression and goblet cell hyperplasia increase mucus viscosity and impair clearance; mucolytics (eg, NAC) and mucin-targeted agents are under investigation (xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10). | 10.3389/fimmu.2024.1404615 (2024); 10.3390/ijms26052184 (2025) |
| Small airway remodeling & emphysema | MMP9, MMP12, TGFB1 (TGF‑β1), COL1A1 | Small airway epithelial cells (CL), Fibroblasts (CL), Smooth muscle cells (CL) | ECM deposition, elastin degradation | Loss and stenosis of terminal bronchioles with peribronchiolar fibrosis and emphysematous alveolar destruction drive irreversible airflow limitation (wechsler2024whateveryclinician pages 11-12, xu2024inflammationmechanismand pages 7-8). | 10.1183/23120541.00177-2024 (2024); 10.3389/fimmu.2024.1404615 (2024) |
| Inflammasome / pyroptosis (NLRP3) | NLRP3, CASP1, IL1B, IL18 | Macrophage (CL), Epithelial cell (CL) | Cytosolic inflammasome assembly → caspase‑1 → GSDMD pores | Mitochondrial ROS and particulate exposures activate NLRP3 → caspase‑1 → IL‑1β/IL‑18 release and pyroptosis, linking exposures to tissue damage (li2024cellularandmolecular pages 11-12, vu2025molecularapproachesto pages 9-10). | 10.3390/ijms25147780 (2024); 10.3390/ijms26052184 (2025) |
| Autoimmunity & B cell follicles | TNFSF13B (BAFF), AICDA, autoantibodies | B cell (CL), T follicular helper cell (CL), Ectopic lymphoid structures | Local germinal center–like activity in lung | Ectopic B‑cell follicles and autoantibodies to modified self-proteins may perpetuate inflammation in subsets of COPD; autoimmune links to comorbidity noted (xu2024inflammationmechanismand pages 7-8). | 10.3389/fimmu.2024.1404615 (2024) |
| Microbiome dysbiosis / interactome | — (taxa-level: Haemophilus, Moraxella, Pseudomonas) | Airway epithelial cells (CL), Macrophages (CL) | Mucus niche / biofilm communities | Loss of antagonistic bacterial interactions and reduced alpha‑diversity associate with worse symptoms, neutrophilic inflammation and exacerbation risk (microbiome–mucus coupling) (vu2025molecularapproachesto pages 9-10, xu2024inflammationmechanismand pages 7-8). | 10.3390/ijms26052184 (2025); 10.3389/fimmu.2024.1404615 (2024) |
| Environmental exposures (PM2.5) synergy | TLR4, NLRP3, RELA (NF‑κB p65) | Epithelial cells (CL), Macrophages (CL), Neutrophils (CL) | Particle uptake, endosomal/mitochondrial ROS | PM2.5 worsens smoke-induced injury by amplifying ROS/NLRP3/caspase‑1 signaling and correlates with worse symptoms/QoL in smokers with COPD (vu2025molecularapproachesto pages 9-10, li2024cellularandmolecular pages 11-12). | 10.3390/ijms26052184 (2025); 10.3390/ijms25147780 (2024) |
| Therapeutics / applications (selected) | IL4R (dupilumab), NFE2L2 (Nrf2 activators), GCLC/GPX (glutathione pathways), PDE4 (PDE4 inhibitors) | Varies by target (immune cells, epithelial targets) | Mechanism-dependent (eg, receptor blockade, antioxidant induction) | Precision biologics (eg, anti‑IL‑4/IL‑13 dupilumab) show benefit in eosinophilic COPD; antioxidants (NAC, Nrf2 agonists), PDE inhibitors, inflammasome inhibitors and senolytics are active translational pathways (~100 molecular/biologic COPD trials ongoing) (vu2025molecularapproachesto pages 12-13, vu2025molecularapproachesto pages 9-10). | 10.3390/ijms26052184 (2025); 10.3389/fimmu.2024.1404615 (2024) |
Table: Compact, citation‑ready summary of major mechanistic axes in COPD (2023–2025), listing key molecules, principal cell types, subcellular locations, short evidence statements, and source DOIs for rapid integration into a knowledge base.
1) Core pathophysiological mechanisms - Chronic inflammation and endotypes: COPD airway inflammation involves neutrophils, macrophages, CD8+ T cells, and in subsets eosinophils/Type 2 biology. Eosinophilic COPD predicts inhaled corticosteroid responsiveness, whereas neutrophilic endotypes often show steroid resistance and benefit from PDE4 inhibition (roflumilast) (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). Systemic inflammation (CRP, IL-6, TNF-α, fibrinogen) associates with comorbidities and outcomes (xu2024inflammationmechanismand pages 7-8). - Protease–antiprotease imbalance: Neutrophil elastase (ELANE) and macrophage MMP12, among other MMPs/serine proteases, overwhelm antiproteases (notably α1-antitrypsin, SERPINA1) leading to elastin destruction and emphysema; α1-antitrypsin deficiency exemplifies causal imbalance (wechsler2024whateveryclinician pages 2-3). - Oxidative stress and mitochondrial dysfunction: Cigarette smoke and pollutants trigger mitochondrial ROS, altered dynamics (fragmentation), impaired mitophagy and bioenergetic defects in airway epithelium and macrophages. Reduced Nrf2/FOXO3a activity diminishes antioxidant defenses; mitochondrial ROS activates NLRP3 and sustains inflammaging (li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). - Cellular senescence: Senescent epithelial and stromal/immune cells exhibit SASP (IL‑6, CXCL8, MMPs), promoting remodeling and persistent inflammation; senescence is a hallmark of accelerated lung ageing in COPD (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 7-8). - Mucus hypersecretion and mucociliary dysfunction: Upregulation of MUC5AC/MUC5B, goblet cell hyperplasia and club-to-goblet transdifferentiation impair clearance and promote mucus plugging; mucolytics and mucoregulators (eg, NAC) target this axis (xu2024inflammationmechanismand pages 1-2, vu2025molecularapproachesto pages 9-10). - Small-airway remodeling and emphysema: Early loss and stenosis of terminal bronchioles with peribronchiolar fibrosis precede emphysema; many patients exhibit mixed pathology (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Inflammasome and pyroptosis: Mitochondrial ROS and particulate exposure activate NLRP3→caspase‑1→IL‑1β/IL‑18, promoting pyroptosis and airway inflammation; PM2.5 synergizes with cigarette smoke to aggravate injury via NLRP3/caspase‑1 (li2024cellularandmolecular pages 11-12, vu2025molecularapproachesto pages 9-10). - Autoimmunity: Ectopic B-cell follicles (tertiary lymphoid structures) and autoantibodies to oxidatively modified self-antigens are reported, potentially sustaining inflammation in severe COPD (xu2024inflammationmechanismand pages 7-8). - Microbiome dysbiosis and interactome disturbance: COPD shows reduced evenness and altered composition in lower airways; during exacerbations antagonistic bacterial interactions diminish and recover post-treatment, linking network disturbance more strongly than diversity to symptoms, lung function and neutrophilic inflammation (xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10).
2) Key molecular players - Genes/proteins: ELANE (neutrophil elastase), MMP12/MMP9, SERPINA1 (α1-antitrypsin), NLRP3, CASP1, IL1B, IL18, TNF, TNFRSF1A (TNFR1), RELA (NF‑κB p65), IL17A, TLR4, EGFR, MUC5AC/MUC5B, HDAC5/6, NFE2L2 (Nrf2), SIRT1, PPARG (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). - Chemical entities: Oxidants/ROS; mucolytic N‑acetylcysteine; PDE4 inhibitor roflumilast; antioxidants and Nrf2 activators (eg, sulforaphane, CDDO-class) in development; macrolides for exacerbation prevention; biologics targeting Type 2 pathways (eg, dupilumab, anti‑IL‑33/TSLP under study) (vu2025molecularapproachesto pages 9-10, vu2025molecularapproachesto pages 12-13). - Cell types: Airway epithelial subsets (basal, ciliated, club, goblet), alveolar type 2 cells; alveolar/interstitial macrophages; neutrophils; CD8+ T cells; B cells within tertiary lymphoid structures; fibroblasts and airway smooth muscle; endothelial cells (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Anatomical locations: Small conducting airways (terminal/respiratory bronchioles), bronchi, alveoli (acini), airway surface liquid/mucus layer; lung interstitium and extracellular matrix (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2).
3) Biological processes (GO) disrupted - Inflammatory response; neutrophil chemotaxis/degranulation; proteolysis; extracellular matrix organization; response to oxidative stress; mitochondrial organization and mitophagy; cellular senescence; mucin biosynthetic process; cilium movement/mucociliary clearance; NLRP3 inflammasome complex assembly; NF‑κB signaling; TLR signaling; IL‑17 signaling (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8).
4) Cellular components (GO) implicated - Mitochondrion (cristae, outer membrane); inflammasome complex (cytosol); nucleus (NF‑κB translocation); extracellular matrix (elastin fibers); apical secretory granules and mucus gel; cilia/axoneme; plasma membrane receptors (EGFR, TLR4, TNFR1) (li2024cellularandmolecular pages 11-12, wechsler2024whateveryclinician pages 2-3).
5) Disease progression and stages - Sequence: Repeated noxious exposures (smoke, biomass, pollution) → oxidative stress and epithelial injury → small-airway inflammation and peribronchiolar fibrosis with loss/stenosis of terminal bronchioles → mucus hypersecretion and mucostasis → parenchymal destruction (emphysema) and persistent airflow limitation. Distinct phenotypes: chronic bronchitis (productive cough with MUC5AC/MUC5B upregulation), emphysema-dominant, and mixed; endotypes span eosinophilic (Type 2-high) and neutrophilic (Type 2-low) inflammation with different therapeutic responses (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2).
6) Phenotypic manifestations (link to mechanisms) - Clinical phenotypes include dyspnea, chronic cough/sputum, recurrent exacerbations, and airflow obstruction. Eosinophilic COPD is associated with steroid responsiveness; neutrophilic COPD correlates with protease burden, NETs, and mucus plugging; mucus–microbiome evolution over time associates with accelerated FEV1 decline and emergence of pathogenic genera (Haemophilus, Moraxella, Pseudomonas) (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 7-8).
7) Microbiome dynamics (stability vs exacerbation) - Lower airway microbiota in COPD exhibits reduced evenness versus controls and shows smoking-related differences; exacerbations are characterized by reduced antagonistic interactions in bacterial networks rather than simple diversity loss, which recover after therapy. Longitudinal cohorts show evolving mucus–microbiome profiles associating with symptom progression and lung function decline (xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10).
Current applications and real-world implementations - Biologics/endotype targeting: Dupilumab (IL‑4Rα blockade, IL‑4/IL‑13 axis) has shown benefit in eosinophilic COPD; alarmin-targeting biologics (anti‑IL‑33/TSLP) are under active study. Clinicians increasingly phenotype by blood eosinophils and exacerbation history to guide ICS or biologics (vu2025molecularapproachesto pages 12-13, wechsler2024whateveryclinician pages 2-3). - Anti-inflammatory small molecules: PDE4 inhibition (roflumilast) benefits chronic bronchitis/neutrophilic phenotypes; long-term macrolides reduce exacerbations but raise resistance concerns (vu2025molecularapproachesto pages 12-13, xu2024inflammationmechanismand pages 7-8). - Mucolytics/mucoregulators: N‑acetylcysteine acts as mucolytic and mucoregulator and is widely used; trials and reviews support effects on mucin expression/viscosity with variable clinical impact across phenotypes (vu2025molecularapproachesto pages 9-10). - Antioxidant/mitochondrial strategies: Nrf2 agonists, glutathione peroxidase mimetics (ebselen), and mitochondria-targeted antioxidants are under investigation to address oxidative stress and mitochondrial quality control defects (vu2025molecularapproachesto pages 9-10, li2024cellularandmolecular pages 11-12). - Inflammasome targeting and pollution mitigation: Preclinical/clinical translational work links PM2.5 to NLRP3 activation; blocking NLRP3/caspase‑1 signaling and environmental exposure reduction represent emerging strategies (vu2025molecularapproachesto pages 9-10).
Statistics and data points from recent studies - Microbiome evenness and diversity: In a protected BAL case–control study (n=97 COPD, n=97 controls), alpha diversity was significantly lower in COPD (Pielou evenness 0.76 vs 0.80, p=0.004; Shannon 3.98 vs 4.34, p=0.01) (Thorax 2024; doi:10.1136/thorax-2023-220455) (xu2024inflammationmechanismand pages 7-8). - Network interactome in exacerbations: Across 1,742 sputum microbiomes, COPD showed reproducibly reduced antagonistic bacterial interactions at stability and further during exacerbation, with recovery post-treatment; loss of antagonistic interactions associated with worse dyspnea, lower lung function, neutrophilia, and higher exacerbation risk (Respiratory Research 2024; doi reported in source) (vu2025molecularapproachesto pages 9-10). - Mucus–microbiome and lung function decline: A longitudinal cohort contrasting accelerated FEV1 decline (~156 ml/year) versus non-decline found increased mucin concentrations (MUC5AC/MUC5B) and emergence of pathogens (e.g., Pseudomonas, Haemophilus) in the accelerated group (AJRCCM 2024; doi:10.1164/rccm.202306-1060OC) (vu2025molecularapproachesto pages 9-10).
Gene/protein annotations with ontology terms - HGNC: ELANE; MMP12; SERPINA1; NLRP3; CASP1; IL1B; IL18; TNF; TNFRSF1A; RELA; IL17A; TLR4; EGFR; MUC5AC; MUC5B; HDAC5; HDAC6; NFE2L2; SIRT1; PPARG (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). - GO Biological Process (selected): inflammatory response; neutrophil degranulation; extracellular matrix organization; response to oxidative stress; regulation of mitophagy; cellular senescence; mucin biosynthetic process; cilium movement; inflammasome complex assembly; NF‑κB signaling (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12). - GO Cellular Component (selected): mitochondrion; inflammasome complex; extracellular region (mucus); cilium; extracellular matrix (elastin fiber) (li2024cellularandmolecular pages 11-12, wechsler2024whateveryclinician pages 2-3). - Cell types (CL): airway epithelial cell (basal, ciliated, club, goblet); alveolar macrophage; neutrophil; CD8+ T cell; B cell; fibroblast; airway smooth muscle cell; endothelial cell (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Anatomical locations (UBERON): small airways (terminal/respiratory bronchioles); bronchi; alveolus; airway surface liquid; pulmonary interstitium (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Chemical entities (ChEBI): reactive oxygen species; N‑acetylcysteine; macrolide antibiotics; phosphodiesterase inhibitors (roflumilast); electrophilic Nrf2 activators (vu2025molecularapproachesto pages 9-10).
Expert opinions and analysis - 2024 ERS Open Research review emphasizes heterogeneity of inflammation, centrality of small-airway disease, and the pathogenic triad framework, urging endotype-driven precision therapy and vigilance for mucus pathology and remodeling (wechsler2024whateveryclinician pages 2-3). 2024 Frontiers in Immunology review underscores mitochondrial dysfunction and immunosenescence, advocating mitochondria-targeted antioxidant strategies and biomarker-guided phenotyping (xu2024inflammationmechanismand pages 7-8). Together, these authoritative sources converge on multi-axis pathobiology and precision approaches.
Citations (URLs and dates) - Wechsler ME, Wells JM. What every clinician should know about inflammation in COPD. ERJ Open Res. 2024 May 20. doi:10.1183/23120541.00177-2024. https://doi.org/10.1183/23120541.00177-2024 (wechsler2024whateveryclinician pages 2-3). - Xu J, Zeng Q, Li S, et al. Inflammation mechanism and research progress of COPD. Front Immunol. 2024 Aug 2. doi:10.3389/fimmu.2024.1404615. https://doi.org/10.3389/fimmu.2024.1404615 (xu2024inflammationmechanismand pages 7-8, xu2024inflammationmechanismand pages 1-2). - Li C‑L, Liu S‑F. Cellular and molecular biology of mitochondria in COPD. Int J Mol Sci. 2024 Jul 18. doi:10.3390/ijms25147780. https://doi.org/10.3390/ijms25147780 (li2024cellularandmolecular pages 11-12). - Meldrum OW, Donaldson GC, et al. Accelerated Lung Function Decline and Mucus–Microbe Evolution in COPD. Am J Respir Crit Care Med. 2024 Aug 1;210(3):298–310. doi:10.1164/rccm.202306-1060OC. https://doi.org/10.1164/rccm.202306-1060OC (vu2025molecularapproachesto pages 9-10). - Tangedal S, et al. Lower airway microbiota in COPD and healthy controls. Thorax. 2024 Feb;79(3):219–226. doi:10.1136/thorax-2023-220455. https://doi.org/10.1136/thorax-2023-220455 (xu2024inflammationmechanismand pages 7-8). - Vu S‑P, Veit K, Sadikot RT. Molecular approaches to treating COPD. Int J Mol Sci. 2025 Feb. doi:10.3390/ijms26052184. https://doi.org/10.3390/ijms26052184 (vu2025molecularapproachesto pages 12-13, vu2025molecularapproachesto pages 9-10, vu2025molecularapproachesto pages 13-14).
Notes and limitations - While mitochondria- and inflammasome‑targeted strategies are promising, large RCT data remain limited as of 2023–2024. Microbiome network analyses provide mechanistic associations but interventional trials targeting interactomes are early-stage. Continued single‑cell and spatial profiling will refine cell‑type–specific mechanisms.
References
(wechsler2024whateveryclinician pages 2-3): Michael E. Wechsler and J. Michael Wells. What every clinician should know about inflammation in copd. ERJ Open Research, 10:00177-2024, May 2024. URL: https://doi.org/10.1183/23120541.00177-2024, doi:10.1183/23120541.00177-2024. This article has 17 citations and is from a peer-reviewed journal.
(xu2024inflammationmechanismand pages 1-2): Jiao Xu, Qingyue Zeng, Shuangqing Li, Qiaoli Su, and Hong Fan. Inflammation mechanism and research progress of copd. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1404615, doi:10.3389/fimmu.2024.1404615. This article has 113 citations and is from a peer-reviewed journal.
(li2024cellularandmolecular pages 11-12): Chin-Ling Li and Shih-Feng Liu. Cellular and molecular biology of mitochondria in chronic obstructive pulmonary disease. International Journal of Molecular Sciences, 25:7780, Jul 2024. URL: https://doi.org/10.3390/ijms25147780, doi:10.3390/ijms25147780. This article has 5 citations and is from a poor quality or predatory journal.
(xu2024inflammationmechanismand pages 7-8): Jiao Xu, Qingyue Zeng, Shuangqing Li, Qiaoli Su, and Hong Fan. Inflammation mechanism and research progress of copd. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1404615, doi:10.3389/fimmu.2024.1404615. This article has 113 citations and is from a peer-reviewed journal.
(vu2025molecularapproachesto pages 9-10): Sheryl-Phuc Vu, Kaleb Veit, and Ruxana T. Sadikot. Molecular approaches to treating chronic obstructive pulmonary disease: current perspectives and future directions. International Journal of Molecular Sciences, 26:2184, Feb 2025. URL: https://doi.org/10.3390/ijms26052184, doi:10.3390/ijms26052184. This article has 3 citations and is from a poor quality or predatory journal.
(wechsler2024whateveryclinician pages 11-12): Michael E. Wechsler and J. Michael Wells. What every clinician should know about inflammation in copd. ERJ Open Research, 10:00177-2024, May 2024. URL: https://doi.org/10.1183/23120541.00177-2024, doi:10.1183/23120541.00177-2024. This article has 17 citations and is from a peer-reviewed journal.
(vu2025molecularapproachesto pages 12-13): Sheryl-Phuc Vu, Kaleb Veit, and Ruxana T. Sadikot. Molecular approaches to treating chronic obstructive pulmonary disease: current perspectives and future directions. International Journal of Molecular Sciences, 26:2184, Feb 2025. URL: https://doi.org/10.3390/ijms26052184, doi:10.3390/ijms26052184. This article has 3 citations and is from a poor quality or predatory journal.
(vu2025molecularapproachesto pages 13-14): Sheryl-Phuc Vu, Kaleb Veit, and Ruxana T. Sadikot. Molecular approaches to treating chronic obstructive pulmonary disease: current perspectives and future directions. International Journal of Molecular Sciences, 26:2184, Feb 2025. URL: https://doi.org/10.3390/ijms26052184, doi:10.3390/ijms26052184. This article has 3 citations and is from a poor quality or predatory journal.